Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neuroendocrine Tumors Unresectable Clear all
Completed Phase 2 Interventional

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT00289627
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab (MDX-010, BMS-734016)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Little Rock, Arkansas • San Francisco, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Jun 25, 2026, 12:10 PM EDT
Active, not recruiting No phase listed Observational

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

NCT05812027
View directory record Official record
Conditions
Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions
Tumor and HLA Profiling
Diagnostic Test
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

NCT00349206
View directory record Official record
Conditions
Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Jun 25, 2026, 12:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

NCT01638676
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Metformin
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 25, 2026, 12:10 PM EDT
Recruiting Phase 3 Interventional

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions
Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
22
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 25, 2026, 12:10 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

NCT03950609
View directory record Official record
Conditions
Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Unresectable Carcinoid Tumor
Interventions
Everolimus, Lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 25, 2026, 12:10 PM EDT
Completed No phase listed Observational

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

NCT02685631
View directory record Official record
Conditions
Localized Non-Resectable Adult Liver Carcinoma
Interventions
Yttrium-90 Resin Microspheres
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Results available

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02159989
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Sapanisertib, Ziv-Aflibercept
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

NCT01239134
View directory record Official record
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jun 25, 2026, 12:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ipilimumab, Sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
257
States / cities
Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 12:10 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

NCT02339571
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2033
U.S. locations
764
States / cities
Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 495 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

NCT01107665
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma
Interventions
Pazopanib and Paclitaxel
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

NCT01469572
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide, Sir-sphere Radioembolization, Everolimus
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Jun 25, 2026, 12:10 PM EDT
Terminated Phase 1 Interventional

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

NCT01611675
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Leflunomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Early Phase 1 Interventional Results available

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

NCT03655756
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Interventions
IFx-Hu2.0
Biological
Lead sponsor
TuHURA Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2022 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma
Interventions
Nivolumab, Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
19
States / cities
San Francisco, California • Orlando, Florida • Louisville, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
View directory record Official record
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tasisulam in Treating Participants With Malignant Melanoma

NCT00383292
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
tasisulam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 25, 2026, 12:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

NCT03325101
View directory record Official record
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Jun 25, 2026, 12:10 PM EDT
Terminated Phase 2 Interventional Results available

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

NCT02203604
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
aldesleukin, ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
CINJRegulatory
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
6
States / cities
Maywood, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jun 25, 2026, 12:10 PM EDT
Completed Phase 2 Interventional

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 25, 2026, 12:10 PM EDT